Teva Pharmaceutical Industries EPS - Earnings per Share 2012-2026 | TEVA
Teva Pharmaceutical Industries annual and quarterly earnings per share history from 2012 to 2026. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Teva Pharmaceutical Industries EPS for the quarter ending March 31, 2026 was $0.31, a 72.22% increase year-over-year.
- Teva Pharmaceutical Industries EPS for the twelve months ending March 31, 2026 was $1.34, a 216.52% decline year-over-year.
- Teva Pharmaceutical Industries 2025 annual EPS was $1.21, a 183.45% decline from 2024.
- Teva Pharmaceutical Industries 2024 annual EPS was $-1.45, a 190% increase from 2023.
- Teva Pharmaceutical Industries 2023 annual EPS was $-0.5, a 77.27% decline from 2022.
| Teva Pharmaceutical Industries Annual EPS | |
|---|---|
| 2025 | $1.21 |
| 2024 | $-1.45 |
| 2023 | $-0.50 |
| 2022 | $-2.20 |
| 2021 | $0.38 |
| 2020 | $-3.64 |
| 2019 | $-0.91 |
| 2018 | $-2.35 |
| 2017 | $-16.26 |
| 2016 | $0.07 |
| 2015 | $1.82 |
| 2014 | $3.56 |
| 2013 | $1.49 |
| 2012 | $2.25 |
| 2011 | $3.09 |
| Teva Pharmaceutical Industries Quarterly EPS | |
|---|---|
| 2026-03-31 | $0.31 |
| 2025-12-31 | $0.42 |
| 2025-09-30 | $0.37 |
| 2025-06-30 | $0.24 |
| 2025-03-31 | $0.18 |
| 2024-12-31 | $-0.19 |
| 2024-09-30 | $-0.39 |
| 2024-06-30 | $-0.75 |
| 2024-03-31 | $-0.12 |
| 2023-12-31 | $0.42 |
| 2023-09-30 | $0.06 |
| 2023-06-30 | $-0.78 |
| 2023-03-31 | $-0.20 |
| 2022-12-31 | $-1.18 |
| 2022-09-30 | $0.05 |
| 2022-06-30 | $-0.21 |
| 2022-03-31 | $-0.86 |
| 2021-12-31 | $-0.14 |
| 2021-09-30 | $0.26 |
| 2021-06-30 | $0.19 |
| 2021-03-31 | $0.07 |
| 2020-12-31 | $0.14 |
| 2020-09-30 | $-3.97 |
| 2020-06-30 | $0.13 |
| 2020-03-31 | $0.06 |
| 2019-12-31 | $0.11 |
| 2019-09-30 | $-0.29 |
| 2019-06-30 | $-0.63 |
| 2019-03-31 | $-0.10 |
| 2018-12-31 | $-2.87 |
| 2018-09-30 | $-0.27 |
| 2018-06-30 | $-0.24 |
| 2018-03-31 | $1.03 |
| 2017-12-31 | $-11.41 |
| 2017-09-30 | $0.52 |
| 2017-06-30 | $-5.94 |
| 2017-03-31 | $0.57 |
| 2016-12-31 | $-1.10 |
| 2016-09-30 | $0.35 |
| 2016-06-30 | $0.20 |
| 2016-03-31 | $0.62 |
| 2015-12-31 | $0.55 |
| 2015-09-30 | $0.12 |
| 2015-06-30 | $0.63 |
| 2015-03-31 | $0.52 |
| 2014-12-31 | $0.80 |
| 2014-09-30 | $1.02 |
| 2014-06-30 | $0.87 |
| 2014-03-31 | $0.87 |
| 2013-12-31 | $0.44 |
| 2013-09-30 | $0.84 |
| 2013-06-30 | $-0.53 |
| 2013-03-31 | $0.74 |
| 2012-12-31 | $0.38 |
| 2012-09-30 | $-0.09 |
| 2012-06-30 | $0.99 |
| 2012-03-31 | $0.97 |
| 2011-12-31 | $0.58 |
| 2011-09-30 | $1.03 |
| 2011-06-30 | $0.64 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $35.437B | $17.258B |
| Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |